Changes in lung function among treated HIV-positive and HIV-negative individuals: analysis of the prospective AGEIV cohort study.

Lancet Healthy Longev

Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Department of Global Health, Amsterdam Institute for Global Health and Development and Amsterdam Public Health Research Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; HIV Monitoring Foundation, Amsterdam, Netherlands.

Published: April 2021

Background: The AGEIV cohort study is a prospective cohort study evaluating the occurrence of age-related comorbidities in people living with and without HIV. We previously reported a lower forced vital capacity (FVC) in HIV-positive compared with HIV-negative participants in those without heavy smoking exposure at time of enrolment in the AGEIV cohort study. In this study we evaluate longitudinal changes in spirometry indices in the same AGEIV cohort accounting for smoking behaviour and other risk factors.

Methods: We obtained pre-bronchodilator spirometry measurements in AGEIV cohort participants during biennial visits over a median of 5·9 years (IQR 5·7-6·0). Adjusted declines in forced expiratory volume in 1 s (FEV), FVC, and FEV/FVC ratio were modelled using linear mixed-effects models and compared by HIV status and smoking status. To evaluate whether changes in spirometry measurements could be driven by increased levels of chronic inflammation, we assessed associations between rates of FEV and FVC decline and CD4 and CD8 T-cell counts, and plasma concentrations of C-reactive protein (CRP), interleukin 6, soluble CD14, soluble CD163, and intestinal fatty-acid-binding protein in separate models. The study is registered at ClinicalTrials.gov, NCT01466582.

Findings: 500 HIV-positive and 481 HIV-negative participants were included with spirometry data from Oct 29, 2010, to Aug 14, 2018. HIV-positive participants were virally suppressed (<40 copies per mL) during 1627 (95%) study visits, and 159 (32%) HIV-positive and 183 (38%) HIV-negative participants had never smoked. Adjusted declines in FEV were 10·0 mL per year faster in HIV-positive non-smokers (95% CI 4·2 to 15·7, p=0·00066) compared with HIV-negative non-smokers, and 11·1 mL per year faster in HIV-positive smokers (95% CI 0·7 to 21·4, p=0·036) compared with HIV-negative smokers. In comparison, smoking was associated with a 16·4 mL per year steeper decline in FEV among HIV-positive participants (95% CI 8·0 to 24·7, p=0·00012), and 15·3 mL per year steeper decline among HIV-negative participants (95% CI 6·7-24·0, p=0·00052) compared with not smoking. Adjusted yearly declines in FEV and FVC, but not FEV/FVC, were significantly greater in HIV-positive than HIV-negative participants overall (additional decline in HIV-positive participants, FEV 10·5 mL per year [95% CI 4·7 to 16·3], p=0·00040; FVC 11·5 mL per year [2·8 to 20·3], p=0·0096; FEV/FVC 0·07% per year [-0·05 to 0·19], p=0·26), with a similar observation for never-smokers (FEV 6·0 mL per year [-1·8 to 13·7], p=0·13; FVC 9·1 mL per year [-3·0 to 21·1], p=0·14; FEV/FVC ratio 0·00% per year [-0·18 to -0·18], p=0·97). Higher CRP concentrations during follow-up were associated with accelerated declines in FEV and FVC among HIV-positive participants but not among HIV-negative participants.

Interpretation: Treated HIV infection was associated with faster declines in both FEV and FVC, but not in the FEV/FVC ratio. These changes were independent of smoking and might have been driven by ongoing interstitial or small airway damage, potentially related to increased inflammation.

Funding: ZonMW, Aidsfonds, Gilead Sciences, ViiV Healthcare, Janssen Pharmaceuticals, Merck.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2666-7568(21)00033-7DOI Listing

Publication Analysis

Top Keywords

ageiv cohort
20
cohort study
16
hiv-negative participants
8
changes spirometry
8
spirometry measurements
8
fev fvc
8
cohort
6
study
6
ageiv
5
changes lung
4

Similar Publications

Background: Mismatch between osteochondral allograft (OCA) donor and recipient sex has been shown to negatively affect outcomes. This study accounts for additional donor variables and clinically relevant outcomes.

Purpose: To evaluate whether donor sex, age, donor-recipient sex mismatch, and duration of graft storage affect clinical outcomes and failure rates after knee OCA transplantation.

View Article and Find Full Text PDF

Background: Many studies have examined the prevalence of acetabular version (AV) and femoral version (FV) abnormalities and their effect on patient-reported outcomes (PROs) after hip arthroscopy for femoroacetabular impingement syndrome (FAIS), but few have explored the prevalence and influence of combined version (CV) abnormalities.

Purpose: To (1) describe the distribution of AV, FV, and CV in the largest cohort to date and (2) determine the relationship between AV, FV, and CV and PROs after hip arthroscopy for FAIS.

Study Design: Cohort study; Level of evidence, 3.

View Article and Find Full Text PDF

Background: Studies are still limited on the isolated effect of retear after arthroscopic rotator cuff repair (ARCR) on functional outcomes after the midterm period.

Purpose: To assess the effect of retear at midterm follow-up after ARCR and to identify factors associated with the need for revision surgery.

Study Design: Cohort study; Level of evidence, 3.

View Article and Find Full Text PDF

Inherited genetics represents an important contributor to risk of esophageal adenocarcinoma (EAC), and its precursor Barrett's esophagus (BE). Genome-wide association studies have identified ∼30 susceptibility variants for BE/EAC, yet genetic interactions remain unexamined. To address challenges in large-scale G×G scans, we combined knowledge-guided filtering and machine learning approaches, focusing on genes with (A) known/plausible links to BE/EAC pathogenesis (n=493) or (B) prior evidence of biological interactions (n=4,196).

View Article and Find Full Text PDF

Background: The armamentarium of medical therapies to treat inflammatory bowel disease (IBD) continues to grow, which has expanded treatment options, particularly after first biologic failure. Currently, there are limited studies investigating the predictive value of first biologic primary non-response (PNR) on subsequent biologic success. Our objective was to determine if PNR to the first biologic for IBD is predictive of response to subsequent biologic therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!